The effects of olmesartan medoxomil on pulse wave velocity and oxidative stress in type2 diabetes mellitus-pulse wave velocity (baPWV, CAVI) subanalysis

The effects of olmesartan medoxomil on pulse wave velocity and oxidative stress in type2 diabetes mellitus-pulse wave velocity (baPWV, CAVI) subanalysis - The effects of olmesartan medoxomil on pulse wave velocity and oxidative stress in type2 diabetes mellitus-pulse wave velocity (baPWV, CAVI) subanalysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006005

Enrollment

Registered

2011-07-20

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

Duration24 weeks Type 2 Diabetes Mellitus Drug therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have systolic blood pressure 130mmHg and/or diastolic blood pressure in type 2 diabetes mellitus

Exclusion criteria

Exclusion criteria: patient who has the impairment of renal function (Cr >2mg/dl) patient who has malabsorption syndrome, the impairment of cerebral blood flow or epilepsy patient who has hyperkalemia patient who has severe cardiac, hepatic or pancreatic disorder patient who has pregnant, nurses a baby or may get pregnant patient who is unsuitable for this study (judged by a doctor)

Design outcomes

Primary

Measure	Time frame
To investigate the effects of olmesartan medoxomil on pulse wave velocity (baPWV, CAVI) in type2 diabetes mellitus	—

Countries

Japan

Contacts

Public ContactMichio Otsuki

Osaka University Graduate School of Medicine Department of Metabolic Medicine

otsuki@endmet.med.osaka-u.ac.jp06-6879-3732

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026